PTD-DBM vs Palmitoyl Tripeptide-38
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif
PTD-DBM is a synthetic peptide studied for hair regrowth. It pairs a cell-penetrating protein transduction domain with a Dishevelled-binding motif, letting it slip into cells and block CXXC5, a natural brake on the Wnt/beta-catenin pathway that hair follicles use to enter their growth phase. In mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. The honest catch: the entire efficacy record is preclinical and comes mostly from one lab. There are no completed human trials, no regulatory approval, and no proof it works on people. For research use only.
Also: Matrixyl synthe'6, Matrixyl Synthe 6
Palmitoyl tripeptide-38 is the active in Sederma's Matrixyl synthe'6, a newer member of the Matrixyl family launched around 2011. It is a three-amino-acid fragment with a fatty acid tail, sold as a wrinkle 'filler from the inside' for forehead lines and crow's feet. It is a cosmetic ingredient, not a drug, and the honest picture is simple: the efficacy claims come almost entirely from the company that makes it.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- PTD-DBM has stronger research evidence (Animal Studies) compared to Palmitoyl Tripeptide-38 (Limited Research).
Detailed Comparison
| Attribute | PTD-DBM | Palmitoyl Tripeptide-38 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans. | The peptide is Pal-Lys-Met(O2)-Lys: lysine, an oxidized methionine (methionine sulfone) and lysine, with a palmitic acid chain attached so it can get into the outer skin more easily. The sequence is taken from connective tissue proteins (collagen VI and laminin), and the idea is the classic 'matrikine' story: small fragments of broken-down matrix proteins act as a signal telling skin cells to make more matrix. Sederma claims it boosts six components in lab tests, which is where the 'synthe'6' name comes from: collagen I, III and IV, fibronectin, hyaluronic acid and laminin-5. That is a plausible signaling mechanism, but it rests on cell culture work by the manufacturer. Whether enough peptide reaches the dermis in real skin to make a measurable difference has not been independently shown. |
| Common Dosing | Supplied as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water approximates the ~6 mg/mL used in the mouse study Once daily to the scalp in most community-reported routines | 2% of the commercial ingredient in a finished product Once or twice daily |
| Administration | Topical (applied to skin) in published research; usually co-applied with valproic acid | Topical (serums, creams) |
| Typical Duration | Applied over several weeks in animal studies | About 2 months in the manufacturer's study before changes were measured; ongoing use to keep any effect |
| Best Time to Take | Not established (topical in animal studies) | Morning and/or evening, on clean skin before moisturizer |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The core evidence comes from Lee SH and colleagues in the Choi laboratory at Yonsei University (South Korea), published in the Journal of Investigative Dermatology in 2017. In mice, topical PTD-DBM sped up the onset of anagen after shaving and promoted wound-induced hair neogenesis; a topical liquid of about 6 mg/mL PTD-DBM plus about 72 mg/mL valproic acid outperformed roughly 2% minoxidil in that model (the study reported these as solution concentrations: 2 mM, 500 mM, and 100 mM). The compound and its CXXC5-targeting mechanism are cited in more recent review articles on Wnt/beta-catenin hair therapies and short peptides for hair loss (2024-2025). What does not exist, as of 2026, is a single completed, peer-reviewed human efficacy trial. There is no FDA approval and no IND on record. Human dosing, safety, pharmacokinetics, and real-world efficacy are all unknown. The preclinical signal is genuinely interesting, but it is a long way from a proven treatment. | There is no independent, peer-reviewed clinical trial of palmitoyl tripeptide-38 on its own that we could find. The main human data is the manufacturer's: a placebo-controlled study in 25 women aged 42 to 70 with forehead lines and crow's feet, using 2% of the Matrixyl synthe'6 ingredient for two months, with reported reductions in wrinkle measures that ranged widely between people. Sederma's launch material in 2011 described visibly smoother forehead and crow's feet wrinkles after two months but gave no published sample sizes or numbers. Where the peptide shows up in published journals, it is usually as one ingredient in a multi-ingredient serum, which cannot isolate its effect. Broader reviews of cosmetic peptides make the same point about this whole category: results are often small, short and unpublished outside company brochures. A 2026 meta-analysis of randomized peptide trials found that topical peptides overall did not produce a significant wrinkle improvement in pooled data. Bottom line: a reasonable, well-tolerated ingredient with a plausible mechanism, but expect mild changes at best and treat the percentage claims as marketing until someone outside the company repeats them. |
Frequently Asked Questions: PTD-DBM vs Palmitoyl Tripeptide-38
What is the difference between PTD-DBM and Palmitoyl Tripeptide-38?
PTD-DBM is a skin & hair peptide that ptd-dbm is a synthetic peptide studied for hair regrowth. it pairs a cell-penetrating protein transduction domain with a dishevelled-binding motif, letting it slip into cells and block cxxc5, a natural brake on the wnt/beta-catenin pathway that hair follicles use to enter their growth phase. in mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. the honest catch: the entire efficacy record is preclinical and comes mostly from one lab. there are no completed human trials, no regulatory approval, and no proof it works on people. for research use only. Palmitoyl Tripeptide-38 is a skin & hair peptide that palmitoyl tripeptide-38 is the active in sederma's matrixyl synthe'6, a newer member of the matrixyl family launched around 2011. it is a three-amino-acid fragment with a fatty acid tail, sold as a wrinkle 'filler from the inside' for forehead lines and crow's feet. it is a cosmetic ingredient, not a drug, and the honest picture is simple: the efficacy claims come almost entirely from the company that makes it. The main differences lie in their mechanisms of action and clinical applications.
Which is better, PTD-DBM or Palmitoyl Tripeptide-38?
Neither is universally "better" - the choice depends on your specific goals. PTD-DBM is typically used for skin & hair purposes, while Palmitoyl Tripeptide-38 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can PTD-DBM and Palmitoyl Tripeptide-38 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using PTD-DBM and Palmitoyl Tripeptide-38 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.